OBJECTIVE: To assess the long-term prognostic value of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) after major vascular surgery. DESIGN: A single-centre prospective cohort study. PATIENTS: 335 patients who underwent abdominal aortic aneurysm repair or lower extremity bypass surgery. INTERVENTIONS: Prior to surgery, baseline NT-proBNP level was measured. Patients were also evaluated for cardiac risk factors according to the Revised Cardiac Risk Index. Dobutamine stress echocardiography (DSE) was performed to detect stress-induced myocardial ischaemia. MAIN OUTCOME MEASURES: The prognostic value of NT-proBNP was evaluated for the endpoints all-cause mortality and major adverse cardiac events (MACE) during long-term follow-up. RESULTS: In this patient cohort (mean age: 62 years, 76% male), median NT-proBNP level was 186 ng/l (interquartile range: 65-444 ng/l). During a mean follow-up of 14 (SD 6) months, 49 patients (15%) died and 50 (15%) experienced a MACE. Using receiver operating characteristic curve analysis for 6-month mortality and MACE, NT-proBNP had the greatest area under the curve compared with cardiac risk score and DSE. In addition, an NT-proBNP level of 319 ng/l was identified as the optimal cut-off value to predict 6-month mortality and MACE. After adjustment for age, cardiac risk score, DSE results and cardioprotective medication, NT-proBNP > or =319 ng/l was associated with a hazard ratio of 4.0 for all-cause mortality (95% CI: 1.8 to 8.9) and with a hazard ratio of 10.9 for MACE (95% CI: 4.1 to 27.9). CONCLUSION: Preoperative NT-proBNP level is a strong predictor of long-term mortality and major adverse cardiac events after major non-cardiac vascular surgery.
OBJECTIVE: To assess the long-term prognostic value of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) after major vascular surgery. DESIGN: A single-centre prospective cohort study. PATIENTS: 335 patients who underwent abdominal aortic aneurysm repair or lower extremity bypass surgery. INTERVENTIONS: Prior to surgery, baseline NT-proBNP level was measured. Patients were also evaluated for cardiac risk factors according to the Revised Cardiac Risk Index. Dobutamine stress echocardiography (DSE) was performed to detect stress-induced myocardial ischaemia. MAIN OUTCOME MEASURES: The prognostic value of NT-proBNP was evaluated for the endpoints all-cause mortality and major adverse cardiac events (MACE) during long-term follow-up. RESULTS: In this patient cohort (mean age: 62 years, 76% male), median NT-proBNP level was 186 ng/l (interquartile range: 65-444 ng/l). During a mean follow-up of 14 (SD 6) months, 49 patients (15%) died and 50 (15%) experienced a MACE. Using receiver operating characteristic curve analysis for 6-month mortality and MACE, NT-proBNP had the greatest area under the curve compared with cardiac risk score and DSE. In addition, an NT-proBNP level of 319 ng/l was identified as the optimal cut-off value to predict 6-month mortality and MACE. After adjustment for age, cardiac risk score, DSE results and cardioprotective medication, NT-proBNP > or =319 ng/l was associated with a hazard ratio of 4.0 for all-cause mortality (95% CI: 1.8 to 8.9) and with a hazard ratio of 10.9 for MACE (95% CI: 4.1 to 27.9). CONCLUSION: Preoperative NT-proBNP level is a strong predictor of long-term mortality and major adverse cardiac events after major non-cardiac vascular surgery.
Authors: Kim A Eagle; Peter B Berger; Hugh Calkins; Bernard R Chaitman; Gordon A Ewy; Kirsten E Fleischmann; Lee A Fleisher; James B Froehlich; Richard J Gusberg; Jeffrey A Leppo; Thomas Ryan; Robert C Schlant; William L Winters; Raymond J Gibbons; Elliott M Antman; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Alice K Jacobs; Loren F Hiratzka; Richard O Russell; Sidney C Smith Journal: Circulation Date: 2002-03-12 Impact factor: 29.690
Authors: E Boersma; D Poldermans; J J Bax; E W Steyerberg; I R Thomson; J D Banga; L L van De Ven; H van Urk; J R Roelandt Journal: JAMA Date: 2001-04-11 Impact factor: 56.272
Authors: A M Richards; R Doughty; M G Nicholls; S MacMahon; N Sharpe; J Murphy; E A Espiner; C Frampton; T G Yandle Journal: J Am Coll Cardiol Date: 2001-06-01 Impact factor: 24.094
Authors: D Poldermans; E Boersma; J J Bax; I R Thomson; L L van de Ven; J D Blankensteijn; H F Baars; T I Yo; G Trocino; C Vigna; J R Roelandt; H van Urk Journal: N Engl J Med Date: 1999-12-09 Impact factor: 91.245
Authors: Stefan K James; Bertil Lindahl; Agneta Siegbahn; Mats Stridsberg; Per Venge; Paul Armstrong; Elliot S Barnathan; Robert Califf; Eric J Topol; Maarten L Simoons; Lars Wallentin Journal: Circulation Date: 2003-07-07 Impact factor: 29.690
Authors: John G Lainchbury; Elizabeth Campbell; Christopher M Frampton; Timothy G Yandle; M Gary Nicholls; A Mark Richards Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: Don Poldermans; Jeroen J Bax; Miklos D Kertai; Boudewijn Krenning; Cynthia M Westerhout; Arend F L Schinkel; Ian R Thomson; Peter J Lansberg; Lee A Fleisher; Jan Klein; Hero van Urk; Jos R T C Roelandt; Eric Boersma Journal: Circulation Date: 2003-04-14 Impact factor: 29.690
Authors: Lisette M Vernooij; Wilton A van Klei; Karel Gm Moons; Toshihiko Takada; Judith van Waes; Johanna Aag Damen Journal: Cochrane Database Syst Rev Date: 2021-12-21
Authors: Amanda A Fox; Charles D Collard; Stanton K Shernan; Christine E Seidman; Jonathan G Seidman; Kuang-Yu Liu; Jochen D Muehlschlegel; Tjorvi E Perry; Sary F Aranki; Christoph Lange; Daniel S Herman; Thomas Meitinger; Peter Lichtner; Simon C Body Journal: Anesthesiology Date: 2009-04 Impact factor: 7.892
Authors: Ji Hyun Yang; Jin Ho Choi; Young-Wook Ki; Dong Ik Kim; Duk-Kyung Kim; Jeong Rang Park; Jae K Oh; Seung-Hyuk Choi Journal: Korean J Intern Med Date: 2012-09-01 Impact factor: 2.884